Enliven Therapeutics “announced that it has entered into a securities purchase agreement for a private investment in public equity, or PIPE, financing that is expected to result in gross proceeds of approximately $90 million, before deducting offering expenses. The financing includes participation from new and existing investors, including Commodore Capital, Fairmount, Venrock Healthcare Capital Partners, a biotech investor, a large mutual fund, Rock Springs Capital, Logos Capital, Woodline Partners LP and Acuta Capital Partners.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ELVN:
- Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
- Enliven reports Q4 EPS (47c), consensus (54c)
- Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
- Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference